Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wirksamkeit und Sicherheit von HB-1 bei Panikstörungen: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie

21. September 2026 aktualisiert von: HB BioTech, LLC

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with Panic Disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.

The study will enroll approximately 240 (up to 600) adult patients who meet the diagnosis of panic disorder.

Patients will be treated for 12 weeks followed by a safety follow up visit one week after their last dose of study treatment.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

170

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Australian Capital Territory
      • Canberra, Australian Capital Territory, Australien, 2617
        • Paratus Clinical Research Canberra
    • New South Wales
      • Blacktown, New South Wales, Australien, 2148
        • Paratus Clinical Research Western Sydney
      • Charlestown, New South Wales, Australien, 2290
        • Novatrials
      • Darlinghurst, New South Wales, Australien, 2010
        • East Sydney Doctors
      • Darlinghurst, New South Wales, Australien, 2010
        • Momentum Clinical Research Darlinghurst
      • Miranda, New South Wales, Australien, 2228
        • Canopy Clinical Sutherland
      • Waitara, New South Wales, Australien, 2077
        • Innovate Clinical Research
      • Westmead, New South Wales, Australien, 2145
        • Westmead Hospital
      • Wollongong, New South Wales, Australien, 2500
        • Canopy Clinical Wollongong
    • Queensland
      • Herston, Queensland, Australien, 4006
        • Paratus Clinical Research Brisbane
      • Mackay, Queensland, Australien, 4740
        • Mackay Hospital and Health Service
    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • South Australian Health and Medical Research Institute
    • Victoria
      • Carlton, Victoria, Australien, 3053
        • NeuroCentrix
      • Frankston, Victoria, Australien, 3199
        • Peninsula Therapeutic and Research Group
      • Melbourne, Victoria, Australien, 3004
        • Ramsay Clinic Albert Road
      • Melbourne, Victoria, Australien, 3004
        • Multidisciplinary Alfred Psychiatry Research Clinic
      • Northcote, Victoria, Australien, 3070
        • Paratus Clinical Research Melbourne
      • Torquay, Victoria, Australien, 3228
        • Clinical Trials Institute
    • Western Australia
      • West Perth, Western Australia, Australien, 6005
        • Clinitrials

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.
  2. Meets Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) Criteria for Panic Disorder.
  3. Minimum of one full, unexpected panic attack in week prior to screening (via Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] based structured interview).
  4. Medically stable on current medication regimen for at least 3 months (including as needed [PRN] medications), as determined by Investigator.
  5. Willing to remain on current doses of other psychiatric medications throughout the length of the trial.
  6. Willing and able to safely stop / avoid any of the following prior to study trial: Inhibitors or inducers of CYP3A4 (grapefruit juice, erythromycin, ritonavir, telithromycin, rifampin), HMG-CoA Reductase Inhibitors (Simvastatin, Lovastatin, Atorvastatin), Beta Blockers (Timolol eyedrops, Metoprolol), Neuromuscular Blocking Agents (curare-like and depolarizing), Antihypertensive Agents (Prazosin and vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers), Inhalation Anesthetics, Disopyramide, Flecainide, Quinidine, Cimetidine, Lithium, Carbamazepine, Phenobarbital, Cyclosporine, Digitalis, Aliskiren, Ramipril and Ramiprilat, aspirin, propranolol.
  7. Willing and able to safely stop / avoid sensitive P-glycoprotein inhibitors.
  8. Willing to take HB-1, telmisartan, verapamil, or placebo.
  9. Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.
  10. Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commit to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms ± spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.
  11. Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening, within 7 days of dosing with study treatment.

Exclusion Criteria:

  1. Any concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.
  2. Concurrent treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) as assessed by clinical interview and urine toxicology testing.
  3. Severe Agoraphobia (Panic Disorder Symptom Severity Scale (PDSS) Item 4 "agoraphobic fear/avoidance" > 2).
  4. Severe Generalized Anxiety (Hamilton Anxiety Rating Scale [HAM-A] Total Score > 23).
  5. Prior lifetime history of suicide attempt, Columbia Suicide Severity Rating Scale (C-SSRS) ≥ 4 in the past 6 months or prior lifetime history of hospitalization for depression.
  6. Diagnosis of Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder or schizoaffective or other psychotic disorders (per Structure Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) [SCID-V].
  7. Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to uncontrolled hypertension, hypotension (defined as below 90/60); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
  8. Any clinically significant electrocardiogram (ECG) abnormalities at screening.
  9. Inadequate hepatic function defined as total bilirubin > 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × the ULN range of each institution.
  10. Inadequate renal function defined as serum creatinine > 1.5 × the upper limit of normal (ULN) range of each institution and/or estimated glomerular filtration rate (eGFR) < 60.
  11. Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.
  12. Any other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
  13. Unable to complete neuropsychological testing.
  14. Already on treatment with either telmisartan or verapamil or both.
  15. Has a history of hypersensitivity or severe allergic reaction to either telmisartan or verapamil, or any component of either licensed drug.
  16. Documented contraindication to taking telmisartan or verapamil: (e.g., Duchenne's muscular dystrophy, myasthenia gravis).
  17. Pregnant or breastfeeding.
  18. Participation in another current clinical trial or prior trial within the last three months.
  19. Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: HB-1

HB-1 fixed dose, once daily.

HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

Andere Namen:
  • Telmisartan/Verapamil-Tablette mit fester Dosis
Experimental: Telmisartan

Telmisartan fixed dose, once daily.

Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.

Andere Namen:
  • Telmisartan
Experimental: Verapamil

Verapamil fixed dose, once daily.

Verapamil will be supplied as a single active pharmaceutical ingredient tablet.

Andere Namen:
  • Verapamil
Placebo-Komparator: Placebo

Placebo treatment, once daily

Matched Placebo will be supplied as a tablet.

Andere Namen:
  • Abgestimmtes Placebo

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Unexpected Panic Attacks
Zeitfenster: Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12

Efficacy will be evaluated through a comparison of the number of unexpected panic attack days (over the last 10 weeks in a 12-week treatment period) from Screening as compared to protocol-specified timepoints per protocol.

Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12
Incidence of Treatment-Emergent Adverse Events
Zeitfenster: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.

Safety will be evaluated through the monitoring of Adverse Events and the review of clinically significant changes in routine laboratory tests, ECGs, and orthostatic vital signs.

Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Clinical Global Impression-Severity Scale (CGI-S)
Zeitfenster: Baseline, Week 4, Week 8 and Week 12

Efficacy will be evaluated through an evaluation in Clinical Global Impression Severity scale (CGI-S) scores from Baseline as compared to protocol-specified timepoints per protocol. The Clinical Global Impression Severity Scale is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients).

Baseline, Week 4, Week 8 and Week 12
Change in Panic Disorder Symptom Severity Scale (PDSS)
Zeitfenster: Screening, Week 4, Week 8 and Week 12

Efficacy will be evaluated through an evaluation in Panic Disorder Symptom Severity Scale (PDSS) scores from Screening as compared to protocol-specified timepoints per protocol.

Screening, Week 4, Week 8 and Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Prof. Malcolm Hopwood, Ramsay Clinic Albert Road

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. Oktober 2024

Primärer Abschluss (Tatsächlich)

9. September 2026

Studienabschluss (Tatsächlich)

9. September 2026

Studienanmeldedaten

Zuerst eingereicht

26. Juni 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. Juni 2024

Zuerst gepostet (Tatsächlich)

3. Juli 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

24. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • HB-PD-002

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .